Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL

被引：0

作者：

Hallek, M. ^{[1
]}

Hillmen, P. ^{[2
]}

Furman, R. R. ^{[3
]}

Coutre, S. E. ^{[4
]}

Sharman, J. P. ^{[5
]}

Pagel, J. M. ^{[6
]}

Barrientos, J. C. ^{[7
]}

Zelenetz, A. D. ^{[8
]}

Kipps, T. J. ^{[9
]}

Flinn, I. W. ^{[10
]}

Ghia, P. ^{[11
]}

Eradat, H. ^{[12
]}

Erwin, T. ^{[13
]}

Lamanna, N. ^{[14
]}

Coiffier, B. ^{[15
]}

Pettitt, A. R. ^{[16
]}

O'Brien, S. M. ^{[17
]}

Cheson, B. D. ^{[18
]}

Ruppert, S. ^{[19
]}

Kroenig, H. ^{[19
]}

Schuster, A. ^{[19
]}

机构：

[1] Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] Weill Cornell Med Coll, New York, NY USA

[4] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA

[5] US Oncol Res, Springfield, OR USA

[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[7] Hofstra North Shore LIJ Sch Med, New Hyde Pk, NY USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Univ Vita Salute San Raffaele, Ist Sci San Raffaele, Milan, Italy

[12] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[13] Florida Canc Specialists, Englewood, CO USA

[14] Columbia Univ, Med Ctr, New York, NY USA

[15] Lyon Sud Univ Hosp, Lyon, France

[16] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

[19] Gilead Sci GmbH, Martinsried, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P191

引用

页码：52 / 53

页数：2

共 50 条

[1] PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL
Hillmen, P.
Furman, R. R.
Coutre, S. E.
Sharman, J. P.
Pagel, J. M.
Barrientos, J. C.
Zelenetz, A. D.
Kipps, T. J.
Flinn, I.
Ghia, P.
Eradat, H. A.
Lamanna, N.
Coiffier, B.
Pettitt, A.
Ye, W.
Jahn, T. M.
Dubowy, R.
O'Brien, S. M.
Hallek, M. J.
Cheson, B. D.
HAEMATOLOGICA, 2014, 99 : 55 - 55
[2] Rituximab linked to fatal infusion-related reactions
Reactions Weekly, 2011, 1356 (1) : 2 - 2
[3] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Freeman, C. L.
Dixon, M.
Houghton, R.
Kreuzer, K-A
Fingerle-Rowson, G.
Herling, M.
Humphrey, K.
Boettcher, S.
de Costa, C. S.
Iglesias, V.
Stilgenbauer, S.
Gribben, J.
Hallek, M.
Goede, V.
LEUKEMIA, 2016, 30 (08) : 1763 - 1766
[4] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
C L Freeman
M Dixon
R Houghton
K-A Kreuzer
G Fingerle-Rowson
M Herling
K Humphrey
S Böttcher
C S de Costa
V Iglesias
S Stilgenbauer
J Gribben
M Hallek
V Goede
Leukemia, 2016, 30 : 1763 - 1766
[5] Infusion-related reactions to infliximab (remicade®) in patients with rheumatoid arthritis:: Relationship to dose, anti-histamine pre-treatment and infusion number
Wasserman, MJ
Weber, DA
Guthrie, JA
Mitroi, E
Bykerk, V
Lee, P
Keystone, EC
JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1888 - 1888
[6] Rituximab infusion-related reactions: clinical prediction model
Reactions Weekly, 2017, 1640 (1) : 11 - 11
[7] Infusion-related reactions to rituximab: frequency, mechanisms and predictors
Paul, Franciane
Cartron, Guillaume
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (04) : 383 - 389
[8] Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
Freeman, Ciara L.
Morschhauser, Franck
Sehn, Laurie
Dixon, Mark
Houghton, Richard
Lamy, Thierry
Fingerle-Rowson, Guenter
Wassner-Fritsch, Elisabeth
Gribben, John G.
Hallek, Michael
Salles, Gilles
Cartron, Guillaume
BLOOD, 2015, 126 (24) : 2646 - 2649
[9] A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
Hayama, Tatsuya
Miura, Katsuhiro
Uchiike, Akihiro
Nakagawa, Masaru
Tsutsumi, Daisuke
Sakagami, Masashi
Yoshida, Yoshikazu
Takei, Masami
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (02) : 380 - 385
[10] A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
Tatsuya Hayama
Katsuhiro Miura
Akihiro Uchiike
Masaru Nakagawa
Daisuke Tsutsumi
Masashi Sakagami
Yoshikazu Yoshida
Masami Takei
International Journal of Clinical Pharmacy, 2017, 39 : 380 - 385

← 1 2 3 4 5 →